Intuitive Surgical filings document operating results, governance matters, capital structure, and material events for a Nasdaq-listed medical technology company focused on robotic-assisted surgery. Its Form 8-K reports furnish quarterly and preliminary financial results, procedure information, and exhibits tied to da Vinci and Ion business performance.
Regulatory filings also cover shareholder voting matters, proxy governance, executive compensation, director elections, and officer-role changes. Other material-event disclosures record completed corporate actions, including the acquisition of da Vinci and Ion distribution operations in Europe, alongside formal disclosures about common stock and financial reporting matters.
Intuitive Surgical, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on April 30, 2026, at 3:00 p.m. Pacific. Proposals include electing ten directors, an advisory vote on executive pay, ratifying PricewaterhouseCoopers as auditor, and approving changes to the 2010 Incentive Award Plan.
The proxy details a planned leadership transition in which longtime CEO Gary S. Guthart became Executive Chair and David J. Rosa was promoted to Chief Executive Officer and director. The Board emphasizes strong governance, with eight of ten nominees independent, a separate Chair and CEO, a lead independent director, annual elections, proxy access, and strict anti‑hedging and anti‑pledging rules.
Operationally, for 2025 Intuitive reported revenue of $10,064.7 million, up 21% from 2024, and income from operations of $2,945.5 million, up 25%. Total da Vinci and Ion procedures reached 3,297,100, up 19%, supported by a growing installed base and multiple new FDA and international clearances for its da Vinci and Ion platforms.
INTUITIVE SURGICAL INC EVP & Chief Medical Officer Myriam Curet exercised options and sold shares in a coordinated transaction. She exercised a non-qualified stock option for 105 shares of common stock at an exercise price of $229.39 per share, then sold the 105 shares of common stock on the same day at an average price of $493.95 per share. The sale was carried out under a pre-arranged Trading Plan that complies with SEC Rule 10b5-1 and expires on July 29, 2026, indicating the timing was pre-scheduled. After these transactions, she directly holds no common shares but indirectly holds 409 shares by trust and continues to hold 1,152 option shares, so the sale represents a relatively small portion of her overall equity exposure to the company.
Myriam Curet McAdams reported multiple sales of Common Stock via Form 144. The filing lists seven transactions between 01/27/2026 and 03/03/2026, totaling 8,080 shares sold for aggregate gross proceeds of $3,985,119.97.
Trades were executed through Morgan Stanley Smith Barney LLC and are identified as stock option exercise and subsequent sales on or about the listed dates.
Intuitive Surgical SVP Mark Brosius reported selling 1,293 shares of Common Stock in open-market transactions. He sold 648 shares at $490.19 per share on March 6, 2026, and 645 shares at $485.01 per share on March 9, 2026. After these sales, he directly holds 1,613 shares. The transactions were executed under a pre-arranged Trading Plan that complies with SEC Rule 10b5-1 and runs through February 14, 2027, indicating these sales were scheduled in advance rather than timed discretionarily.
Intuitive Surgical senior executive Mark Brosius reported open-market sales of company common stock. As SVP and Chief Manufacturing and Supply Chain Officer, he sold a total of 3,658 shares across three transactions on March 3, 4, and 5, 2026.
The sales were executed at weighted-average prices of about $488.10, $498.6804, and $495.20 per share, with detailed price ranges provided in the footnotes. After these transactions, he directly held 2,906 shares of Intuitive Surgical common stock. All sales took place under a Trading Plan that complies with SEC Rule 10b5‑1 and expires on February 14, 2027.
Mark Brosius reported sales of ISRG common stock under 10b5-1 plans. The filing lists multiple 10b5-1 sales including 03/04/2026 sales of 431 shares for $213,426.89 and 1,931 shares for $964,456.23, 03/03/2026 sales of 431 shares for $209,974.58 and 217 shares for $106,314.22, 12/15/2025 sale of 464 shares for $254,499.36, and 12/12/2025 sales of 4,500 shares for $2,463,120.00 and 312 shares for $170,776.32.
The filing also lists securities to be sold as Performance Stock Units (522, 02/28/2026) and Restricted Stock Units (1,192, 02/10/2026).
ISRG reports a sale notice by an insider and scheduled restricted stock unit dispositions. A 10b5-1 sale executed 02/18/2026 shows 647 common shares sold for $323,500. The filing lists restricted stock units to be sold: 1,163 with date 02/26/2026 and 7,205 with date 02/28/2026, with Morgan Stanley Smith Barney LLC as broker.
Intuitive Surgical VP Corporate Controller Fredrik Widman reported planned share sales and RSU vesting activity. He sold 249 shares of common stock on February 27, 2026 at $499.71 per share, and 118 shares on March 3, 2026 at $487.18 per share in open-market transactions under a Rule 10b5-1 trading plan that runs through May 21, 2026.
These sales followed the vesting of 468 restricted stock units on February 28, 2026, which converted into the same number of common shares. To cover statutory tax withholding on the vesting, 233 shares of common stock were disposed of at $503.51 per share. After these transactions, Widman directly held just over one thousand common shares.
Intuitive Surgical EVP & Chief Medical Officer Myriam Curet reported net insider sales of common stock through a trust. A trust associated with her sold 4,728 shares on March 3, 2026 at an average price of $487.18 per share, leaving 409 indirectly owned shares.
On March 2, 2026, a non-qualified stock option for 125 shares was exercised and converted into common stock at an exercise price of $208.90 per share, and those 125 shares were then sold the same day at $492.59 per share. The option position now shows zero shares remaining. The transactions were carried out under a Trading Plan that complies with SEC Rule 10b5-1 and expires on July 29, 2026.